Roche anti-TIGIT therapy fails to extend survival in late-stage lung cancer trial
seekingalpha
2024-11-26
Michael Vi/iStock Editorial via Getty Images
Genentech, a unit of Roche (OTCQX:RHHBF), announced Tuesday that its anti-TIGIT immunotherapy tiragolumab as part of a combination regimen failed to reach the primary endpoint of overall survival in a late-stage trial for certain patients with lung cancer.
The outcome
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
熱議股票
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10